Role fo O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 1111-1116

  Hansen, Ryan J ^a   Nagasubramanian, Ramamoorthy ^a   Delaney, Shannon M ^a   Samson, Leona D ^b   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ACROLEIN; ALKYLATING AGENT; CARMUSTINE; CHLOROACETALDEHYDE; CYCLOPHOSPHAMIDE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DACARBAZINE; DRUG DERIVATIVE; GUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA REPAIR; ENZYME DEFICIENCY; GENE FREQUENCY; GENE MUTATION; IN VIVO STUDY; MOUSE; MUTAGENICITY; MUTANT; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TOXICITY TESTING; WILD TYPE; ANIMAL; DRUG ANTAGONISM; GENETIC TRANSFECTION; MALE; MUTAGEN TESTING; MUTATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALKYLATING AGENTS; ANIMALS; CARMUSTINE; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DACARBAZINE; GUANINE; MALE; MICE; MICE, TRANSGENIC; MUTAGENICITY TESTS; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSFECTION;

EID: 34447096146     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl218     Document Type: Article

References (49)

1. Davies, S.M. (2001) Therapy-related leukemia associated with alkylating agents. Med. Pediatr. Oncol., 36, 536-540.
2. 6-alkylguanine by alkyltransferases. Mutat. Res., 462, 83-100.
3. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 51, 167-223.
4. 6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry, 35, 1328-1334.
5. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis, 23, 823-830.
6. Kaina, B. (2004) Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: A long road traveled and still a far way to go. Cytogenet. Genome Res., 104, 77-86.
7. Tong, W.P. et al. (1982) Formation of the cross-link 1-[N3-deoxycytidyl], 2-[Nl-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res., 42, 3102-3105.
8. 6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res. 16, 6779-6788.
9. 6-methylguanine-DNA methyltransferase. Nucleic Acids Res., 11, 7743-7758.
10. Belanich, M. et al. (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res., 56, 783-788.
11. Dolan, M.E. et al. (1990) Depletion of mammalian O 6-alkylguanine-DNA alkyltransferase activity by O 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad Sci. USA, 87, 5368-5372.
12. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51, 3367-3372.
13. Pegg, A.E. et al. (1995) Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O 6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Biochem. Pharmacol., 50 1141-1148.
14. 6-benzylguanine and 1,3-bis(2-chloroethyl -l-nitrosourea in advanced melanoma. Clin. Cancer Res., 11, 7861-7865.
15. Quinn, J.A. et al. (2005) Phase I trial of temozolomide plus O 6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol., 23, 7178-7187.
16. Quinn, J.A. et al. (2002) Phase II trial of carmustine plus O 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol., 30, 2277-2283.
17. 6-benzylguanine in patients with recurrent malignant glioma abstract from the Society for Neuro-Oncology Eighth Annual Meeting. Neuro-oncol., 5, 279-360.
18. Colvin, O.M. (1999) An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des., 5, 555-560.
19. Ludeman, S.M. (1999) The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des., 5, 627-643.
20. 6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res., 59, 3059-3063.
21. 6-alkyiguanine-DNA alkyltransferase. Cancer Chemother. Pharmacol., 43, 80-85.
22. Allay, E. et al. (1999) Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene, 18, 3783-3787.
23. 6-alkylguanine-DNA alkyltransferase. Science, 259, 219-222.
24. 6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res., 54, 4648-4652.
25. Zaidi, N.H. et al. (1995) Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis, 16, 451-456.
26. Becker, K. et al. (1997) The DNA repair protein O 6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineo-plastic chloroethylnitrosourea. Cancer Res., 57, 3335-3338.
27. Glassner, B.J. et al. (1999) DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis, 14, 339-347.
28. 6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU)-induced long-term toxicities. J. Pharmacol. Exp. Ther., 315, 1247-1255.
29. Jones, I.M. et al. (1985) A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. Mutat. Res., 147, 97-105.
30. Shiraishi, A. et al. (2000) Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis, 21, 1879-1883.
31. Tsuzuki, T. et al. (1996) Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis, 17, 1215-1220.
32. 6-alkylguanine-DNA alkyltransferases. Cancer Res., 60, 5464-5469.
33. 6-alkylguanine-DNA alkyltransferase. Cancer Res., 53, 997-1003.
34. Dann, E.J. et al. (2001) Biology and therapy of secondary leukaemias. Best Pract. Res. Clin. Haematol., 14, 119-137.
35. Perry J.R. et al. (1998) Acute leukemia following treatment of malignant glioma. J. Neuro-oncol., 40, 39--46.
36. De Vita, S. et al. (2005) Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann. Hematol., 84, 760-762.
37. Su, Y.W. et al. (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neuro-oncol. 71, 315-318.
38. Geiger, H. et al. (2006) Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood, 107, 3010-3011.
39. Friedman, H.S. et al. (2000) Temozolomide and treatment of malignant glioma. Clin. Cancer Res., 6, 2585-2597.
40. Sakumi, K. et al. (1997) Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res., 57, 2415-2418.
41. Ryan, C.W. et al. (2006) A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother. Pharmacol, 58, 634-639.
42. 6-(2-chloroethyl) guanine mediates the biological effects of chloroethylnitrosoureas. Environ. Health Perspect., 62, 119-126.
43. 6-benzyl-2-deoxyguanosine. Clin. Cancer Res., 9, 3801-3807.
44. Allan J.M. et al. (1998) Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res., 58, 3965-3973.
45. 6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol. Pharmacol., 52, 815-820.
46. Gorelick, N.J. et al. (1999) Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacl transgenic mice. Environ. Mol. Mutagen., 34, 154-166.
47. Gamcsik, M.P. et al. (1999) Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharm. Des., 5, 587-605.
48. 6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Mol. Cancer Ther., 1, 21-28.
49. Smith, S.M. et al. (2003) Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother. Pharmacol., 52, 291-302.